Chronic Myeloid Leukemia (CML) Treatment Market Report 2026

Chronic Myeloid Leukemia (CML) Treatment Market Overview

• Chronic Myeloid Leukemia (CML) Treatment market size has reached to $8.64 billion in 2025 • Expected to grow to $12.17 billion in 2030 at a compound annual growth rate (CAGR) of 7.2% • Growth Driver: Rising Incidence Of Chronic Myeloid Leukemia (CML) • Market Trend: Strategic Partnership To Propel The Market Need • North America was the largest region in 2025.

What Is Covered Under Chronic Myeloid Leukemia (CML) Treatment Market?

Chronic myeloid leukemia (CML) treatment refers to the treatment of chronic myeloid leukemia. Cancer of the blood and bone marrow is called chronic myeloid leukemia (CML). It is characterized by the uncontrolled growth of abnormal white blood cells called myeloid cells. These cells are usually responsible for fighting infections and maintaining the body's immune system. The main types of chronic myeloid leukemia (CML) treatment are targeted therapy, chemotherapy, radiation therapy, splenectomy, and stem cell transplant. Targeted therapy refers to a type of cancer treatment where drugs are used to specifically target the genes and proteins that support the growth and survival of cancer cells. Targeted therapy in chronic myeloid leukemia (CML) treatment is used to recognize and destroy particular cancer cell types while sparing healthy cells for injury. The various drugs include tyrosine kinase inhibitors, antimetabolites, and others that are used in hospitals, clinics, and others. The medicines related to chronic myeloid leukemia (CML) treatment are available in hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Chronic Myeloid Leukemia (CML) Treatment Market Growth Forecast?

The chronic myeloid leukemia (cml) treatment market size is expected to see strong growth in the next few years. It will grow to $12.17 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing development of novel targeted agents, rising adoption of combination therapies, expansion of precision oncology programs, growing focus on treatment adherence, increasing investments in oncology research. Major trends in the forecast period include increasing adoption of targeted therapy regimens, rising use of next-generation tkis, growing focus on molecular diagnostics, expansion of personalized treatment protocols, enhanced emphasis on long-term disease management.

Global Chronic Myeloid Leukemia (CML) Treatment Market Segmentation

1) By Type: Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy, Stem Cell Transplant 2) By Drug Type: Tyrosine Kinase Inhibitors, Antimetabolites, Other Drug Types 3) By Application: Hospitals, Clinic, Other Applications 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), BCR-ABL Inhibitors, Monoclonal Antibody Therapy, Signal Transduction Inhibitors 2) By Chemotherapy: Alkylating Agents, Antimetabolites, Anthracyclines, Combination Chemotherapy Regimens 3) By Radiation Therapy: External Beam Radiation Therapy, Total Body Irradiation, Radioimmunotherapy 4) By Splenectomy: Partial Splenectomy, Total Splenectomy 5) By Stem Cell Transplant: Allogeneic Hematopoietic Stem Cell Transplant, Autologous Stem Cell Transplant

What Is The Driver Of The Chronic Myeloid Leukemia (CML) Treatment Market?

The rising incidence and prevalence of chronic myeloid leukemia (CML) population is expected to propel the growth of the chronic myeloid leukemia (CML) treatment market going forward. Chronic myeloid leukemia, also known as chronic myelogenous leukemia, is a type of cancer that affects the bone marrow and blood. It is characterized by the overproduction of immature white blood cells called myeloid cells. Chronic myeloid leukemia (CML) treatment helps to slow the progression of cancer and stop it from reaching an advanced phase. For instance, in March 2023, according to the American Society of Clinical Oncology, a US-based professional organization representing physicians of all oncology sub-specialties, in the United States, in 2023, around 35,730 persons (19,860 men and 15,870 women) are anticipated to receive a multiple myeloma diagnosis and 12,590 deaths from this illness are anticipated in 2023 (7,000 males and 5,590 women). Therefore, the rising incidence and prevalence of chronic myeloid leukemia (CML) population is driving the growth of the chronic myeloid leukemia (CML) treatment industry going forward.

Key Players In The Global Chronic Myeloid Leukemia (CML) Treatment Market

Major companies operating in the chronic myeloid leukemia (cml) treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Incyte Corporation, Cipla Limited, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Innovent Biologics Inc., Glenmark Pharmaceuticals Limited, Il-Yang Pharmaceutical Co. Ltd., Accord Healthcare Inc., ARIAD Pharmaceuticals Inc., Orca Bio, Bio-Path Holdings Inc.

Global Chronic Myeloid Leukemia (CML) Treatment Market Trends and Insights

Major companies operating in the chronic myeloid leukemia (CML) treatment market are focusing on forming strategic partnerships and collaborations to expand their product portfolios, accelerate commercialization, and enhance geographic reach. Such alliances enable biotechnology companies to leverage specialized expertise in market access, regulatory guidance, and oncology commercialization to bring innovative therapies to patients more efficiently. For instance, in February 2023, Xspray Pharma, a Sweden-based biotechnology company, partnered with EVERSANA, a US-based life sciences commercialization firm, to support the U.S. launch and commercialization of its product Dasynoc (XS004) for the treatment of chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL). Dasynoc, a new and differentiated therapeutic option pending FDA approval and legal conditions, is expected to enter the $3.5 billion U.S. market for tyrosine kinase inhibitors. Through this partnership, Xspray Pharma will gain access to EVERSANA’s dedicated oncology-focused commercialization team, enabling a customized and efficient market entry strategy. Planned for launch in the second half of 2023, Dasynoc is anticipated to significantly improve treatment options for patients with CML and ALL in the United States.

What Are Latest Mergers And Acquisitions In The Chronic Myeloid Leukemia (CML) Treatment Market?

In January 2025, Handa Therapeutics, a US-based pharmaceutical company, acquired the FDA-approved Chronic Myeloid Leukemia (CML) drug PHYRAGO (dasatinib) tablets for an undisclosed amount. With this acquisition, Handa Therapeutics aims to strengthen its oncology portfolio, expand access to targeted CML therapies, accelerate revenue growth through an established, regulatory-cleared product, and enhance its strategic position in the hematologic malignancies market. Nanocopoeia, LLC is a US-based research company.

Regional Outlook

North America was the largest region in the chronic myeloid leukemia (CML) treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chronic Myeloid Leukemia (CML) Treatment Market?

The chronic myeloid leukemia (CML) treatment market includes revenues earned by entities by providing targeted therapy with tyrosine kinase inhibitors (TKIs). The chronic myeloid leukemia market includes Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Asciminib. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chronic Myeloid Leukemia (CML) Treatment Market Report 2026?

The chronic myeloid leukemia (cml) treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chronic myeloid leukemia (cml) treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.